CoChat

Treatment of ADHD: Drugs, psychological therapies, devices, complementary and alternative methods as well as the trends in clinical trials

Open access

The DOI matches its Crossref record; 96 of the 96 references it cites were found in a registry or an index.

Abstract

Attention-deficit/hyperactivity disorder (ADHD) is one of the most common neurodevelopmental disorders having a high influence on social interactions. The number of approved treatments and clinical trials for ADHD have increased markedly during the recent decade. This analytical review provides a quantitative overview of the existing pharmacological and non-pharmacological methods of ADHD treatments investigated in clinical trials during 1999–2021. A total of 695 interventional trials were manually assessed from clinicaltrial.gov with the search term « ADHD», and trial data has been used for analysis. A clear majority of the studies investigated non-pharmacological therapies (∼80%), including many behavioral options, such as social skills training, sleep and physical activity interventions, meditation and hypnotherapy. Devices, complementary and other alternative methods of ADHD treatment are also gaining attention. The pharmacological group accounts for ∼20% of all the studies. The most common drug classes include central nervous system stimulants (e.g., methylphenidate hydrochloride, lisdexamfetamine dimesylate, amphetamine sulfate, mixed amphetamine salts, a combination of dexmethylphenidate hydrochloride and serdexmethylphenidate chloride), selective noradrenaline reuptake inhibitors (atomoxetine, viloxazine), and alpha2 adrenergic receptor agonists (guanfacine hydrochloride, clonidine hydrochloride). Several studies investigated antidepressants (e.g., bupropion hydrochloride, vortioxetine), and atypical antipsychotics (e.g., quetiapine, aripiprazole) but these are yet not approved by the FDA for ADHD treatment. We discuss the quantitative trends in clinical trials and provide an overview of the new drug agents and non-pharmacological therapies, drug targets, and novel treatment options.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fphar.2022.1066988

Cites

96 of 96 references verified0 citation errors · 0 not checkable

Statistics

Figures

FIGURE 1 The figure presents information about the number of trials among the most widely used pharmacological classes of drugs applied for ADHD treatment in two time intervals (1999–2009 and 2010–2020). The colors of the slices comply with the pharmacological classes. The data is due 4 January 2021.
FIGURE 1 The figure presents information about the number of trials among the most widely used pharmacological classes of drugs applied for ADHD treatment in two time intervals (1999–2009 and 2010–2020). The colors of the slices comply with the pharmacological classes. The data is due 4 January 2021.CC BY · PubMed Central
FIGURE 2 (A) Most common drug targets in ADHD trials. This figure shows targets with the highest number of unique agents drugging the corresponding target in ADHD clinical trials. If a drug had multiple targets, all of these targets were included in the analysis. Protein names have been used to distinguish targets. In total, 12 most common drug targets were included in the figure: sodium-dependent noradrenaline transporter (SLC6A2), sodium-dependent dopamine transporter (SLC6A2), D (2) dopamine receptor (DRD2), sodium-dependent serotonin transporter (SLC6A2), neuronal acetylcholine receptor subunit alpha-4 (CHRNB2), neuronal acetylcholine receptor subunit beta-2 (CHRNA4), 5-hydroxytryptamine receptor 2A (HTR2A), synaptic vesicular amine transporter (SLC18A2), histamine H3 receptor (HRH3), alpha-2A adrenergic receptor (ADRA2A), neuronal acetylcholine receptor subunit alpha-7 (CHRNA7) and alpha-2C adrenergic receptor (ADRA2C). (B) Drug target types in ADHD studies. All data regarding drug target type was collected from go.drugbank.com, genome. jp, and uniprot.org. In order to construct this figure, all unique gene names used in the analysis (82 in total) were taken and then transformed into protein names. Then corresponding proteins have been classified according to four target types: receptor, enzyme, ion channel, transporter. For the gene names S100B (S100 Calcium Binding Protein (B), CARTPT (Cocaine- and amphetamine-regulated transcript protein), and M (Matrix protein 2) no information about the protein type was found, and thus they were placed in group “other”. The data is due 4 January 2021.
FIGURE 2 (A) Most common drug targets in ADHD trials. This figure shows targets with the highest number of unique agents drugging the corresponding target in ADHD clinical trials. If a drug had multiple targets, all of these targets were included in the analysis. Protein names have been used to distinguish targets. In total, 12 most common drug targets were included in the figure: sodium-dependent noradrenaline transporter (SLC6A2), sodium-dependent dopamine transporter (SLC6A2), D (2) dopamine receptor (DRD2), sodium-dependent serotonin transporter (SLC6A2), neuronal acetylcholine receptor subunit alpha-4 (CHRNB2), neuronal acetylcholine receptor subunit beta-2 (CHRNA4), 5-hydroxytryptamine receptor 2A (HTR2A), synaptic vesicular amine transporter (SLC18A2), histamine H3 receptor (HRH3), alpha-2A adrenergic receptor (ADRA2A), neuronal acetylcholine receptor subunit alpha-7 (CHRNA7) and alpha-2C adrenergic receptor (ADRA2C). (B) Drug target types in ADHD studies. All data regarding drug target type was collected from go.drugbank.com, genome. jp, and uniprot.org. In order to construct this figure, all unique gene names used in the analysis (82 in total) were taken and then transformed into protein names. Then corresponding proteins have been classified according to four target types: receptor, enzyme, ion channel, transporter. For the gene names S100B (S100 Calcium Binding Protein (B), CARTPT (Cocaine- and amphetamine-regulated transcript protein), and M (Matrix protein 2) no information about the protein type was found, and thus they were placed in group “other”. The data is due 4 January 2021.CC BY · PubMed Central
FIGURE 3 For the four main classes of interventions such as pharmacological interventions, devices, psychological and complementary and alternative interventions, unique new agents and methods per year were taken. If a study had several interventions, all of them were considered separately. The data is due 4 January 2021.
FIGURE 3 For the four main classes of interventions such as pharmacological interventions, devices, psychological and complementary and alternative interventions, unique new agents and methods per year were taken. If a study had several interventions, all of them were considered separately. The data is due 4 January 2021.CC BY · PubMed Central
FIGURE 4 (A) Number of clinical trials per year divided by phases. This figure provides a graphical representation of the number of studies per year for pharmacological, psychological and complementary and alternative methods, categorized by a trial phase for the whole analyzed period (1999–2020). In total, 644 studies were included in the analysis. (B) Number of clinical trials per year divided by stages. For devices, division by stages was used. Stages have been classified as follows: traditional feasibility, first-in-human, and early feasibility stages have been classified as exploratory stage, the pivotal stage has been left as is. This figure shows the number of device studies for the time period from 1999 to 2020. In total, 51 studies were included. The data is due 4 January 2021.
FIGURE 4 (A) Number of clinical trials per year divided by phases. This figure provides a graphical representation of the number of studies per year for pharmacological, psychological and complementary and alternative methods, categorized by a trial phase for the whole analyzed period (1999–2020). In total, 644 studies were included in the analysis. (B) Number of clinical trials per year divided by stages. For devices, division by stages was used. Stages have been classified as follows: traditional feasibility, first-in-human, and early feasibility stages have been classified as exploratory stage, the pivotal stage has been left as is. This figure shows the number of device studies for the time period from 1999 to 2020. In total, 51 studies were included. The data is due 4 January 2021.CC BY · PubMed Central
FIGURE 5 (A) Figure 5A illustrates quantitative trends for pharmacological, psychological, complementary and alternative methods and devices. It shows the number of phase 1 studies per year for each method, exept devices, starting from 1999. In oder to show quantitative trends for the device group, studies in exploratory stage were taken. Traditional feasibility, first-in-human, and early feasibility studies have been classified as exploratory stage studies. If there was a combination of interventions in the study, each intervention in this combination was considered separately. (B) Figure 5B depicts in more detail quantitative trends for the psychological group after its division into smaller subclasses: behavior management, cognitive training and psychoeducation. (C) Figure 5C provides information about quantitative trends distribution for complementary and alternative methods class when divided into supplementary and mind-body intervention groups. The data is due 4 January 2021.
FIGURE 5 (A) Figure 5A illustrates quantitative trends for pharmacological, psychological, complementary and alternative methods and devices. It shows the number of phase 1 studies per year for each method, exept devices, starting from 1999. In oder to show quantitative trends for the device group, studies in exploratory stage were taken. Traditional feasibility, first-in-human, and early feasibility studies have been classified as exploratory stage studies. If there was a combination of interventions in the study, each intervention in this combination was considered separately. (B) Figure 5B depicts in more detail quantitative trends for the psychological group after its division into smaller subclasses: behavior management, cognitive training and psychoeducation. (C) Figure 5C provides information about quantitative trends distribution for complementary and alternative methods class when divided into supplementary and mind-body intervention groups. The data is due 4 January 2021.CC BY · PubMed Central
FIGURE 6 (A) Number of agents per category and maximal reached phase. The number of discontinued and active agents per category. This graph presents information about unique agents and their maximal reached phase in the following classes: antidepressants, central nervous system stimulants, alpha2 adrenergic receptor agonists, AMPA receptor positive allosteric modulators, alpha7 neuronal nicotinic acetylcholine receptor agonists, antiparkinsonian, atypical antipsychotics, dementia therapeutic agents, histamine H3 receptor antagonists, nootropics, sedative-hypnotics, selective noradrenaline reuptake inhibitors, typical antipsychotics. The colors of the bars show the maximal reached phase or approval status. The right side of the graph depicts the number of active or discontinued agents in the classes presented on the left side. The drug was classified as active if it was not approved and there were clinical trials on it after 2018. The drug was classified as discontinued if it was not approved, and there were no active clinical trials on it after 2018. If there was no completion date for the agent, it was placed in the “without a date” category. The length of the bars is proportional to the number of agents. The colors of the bars show the agent category. (B) Ongoing trials and approved agents The pie charts show the distribution of drug classes in ongoing clinical trials and among approved ADHD agents. The colors of the slices correspond to the pharmacological classes. Trials have been sub-categorized by phase. The data is due 4 January 2021. Abbreviations: ADHD, attention deficit hyperactivity disorder; α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor, AMPA receptor.
FIGURE 6 (A) Number of agents per category and maximal reached phase. The number of discontinued and active agents per category. This graph presents information about unique agents and their maximal reached phase in the following classes: antidepressants, central nervous system stimulants, alpha2 adrenergic receptor agonists, AMPA receptor positive allosteric modulators, alpha7 neuronal nicotinic acetylcholine receptor agonists, antiparkinsonian, atypical antipsychotics, dementia therapeutic agents, histamine H3 receptor antagonists, nootropics, sedative-hypnotics, selective noradrenaline reuptake inhibitors, typical antipsychotics. The colors of the bars show the maximal reached phase or approval status. The right side of the graph depicts the number of active or discontinued agents in the classes presented on the left side. The drug was classified as active if it was not approved and there were clinical trials on it after 2018. The drug was classified as discontinued if it was not approved, and there were no active clinical trials on it after 2018. If there was no completion date for the agent, it was placed in the “without a date” category. The length of the bars is proportional to the number of agents. The colors of the bars show the agent category. (B) Ongoing trials and approved agents The pie charts show the distribution of drug classes in ongoing clinical trials and among approved ADHD agents. The colors of the slices correspond to the pharmacological classes. Trials have been sub-categorized by phase. The data is due 4 January 2021. Abbreviations: ADHD, attention deficit hyperactivity disorder; α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor, AMPA receptor.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 96 references

Research works printed but not linked: 5

  1. 2013, Diagnostic and Statistical Manual of Mental Disorders
  2. Multi-discipline review for AZSTARYS
  3. Press release Announcement2020
  4. Press release Announcement2021
  5. Press release Announcement2022

Cited by

See all 145

Metadata

Authors
Nazarova, V. A., Sokolov, A. V., Chubarev, V. N., Tarasov, V. V., & Schiöth, H. B.
Affiliations
Uppsala University (SE)
Corresponding author
Schiöth, Helgi B.
Venue
Frontiers in Pharmacology
Published
2022-11-17
Volume
13
Pages
1066988-1066988
ISSN
1663-9812 (ISSN-L)
OpenAlex
W4309604196
Cited by
111
References
96
Citations by year
2026: 24 · 2025: 51 · 2024: 24 · 2023: 12
FWCI
3.74
Type
journal article
Language
en
Open access
Locations
  • Frontiers in Pharmacology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Uppsala University Publications (Uppsala University) (submittedVersion, other-oa)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
Brain Research Foundation
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
  • Social Sciences › Psychology › Developmental and Educational Psychology › Behavioral and Psychological Studies
  • Life Sciences › Neuroscience › Cognitive Neuroscience › Autism Spectrum Disorder Research
Keywords
attention deficit hyperactivity disorder, ADHD treatment, pharmacotherapy, non-pharmacological treatment, psychostimulants, methylphenidate, atomoxetine, guanfacine, clonidine, noradrenergic reuptake inhibitors, antidepressants, atypical antipsychotics, behavioral interventions, social skills training, meditation, hypnotherapy, sleep interventions, physical activity interventions, clinical trial trends, therapeutic target, complementary and alternative medicine

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Treatment of ADHD: Drugs, psychological therapies, devices, complementary and alternative methods as well as the trends in clinical trials. https://app.cochat.ai/papers/10.3389/fphar.2022.1066988
The paper
Nazarova, V. A., Sokolov, A. V., Chubarev, V. N., Tarasov, V. V., & Schiöth, H. B. (2022). Treatment of ADHD: Drugs, psychological therapies, devices, complementary and alternative methods as well as the trends in clinical trials. Frontiers in Pharmacology. https://doi.org/10.3389/fphar.2022.1066988

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.